子宮筋腫治療の世界市場：2025年～2033年

世界の子宮筋腫治療の市場規模は2024年に15億8,000万米ドルとなりました。同市場は、2033年には35億7,000万米ドルに達すると予測され、予測期間の2025年～2033年には9.5％のCAGRで拡大するとみられています。

子宮筋腫（平滑筋腫とも呼ばれる）は、子宮内または子宮壁に形成される筋肉と組織からなる増殖物です。これらの増殖は通常良性であり、女性に最もよくみられる非がん性腫瘍です。子宮筋腫は、痛みや多量の不規則な膣出血など、さまざまな症状を引き起こすことがあります。症状がなく、子宮筋腫があることに気づかないこともあります。子宮筋腫の治療は通常、症状の重さによって異なります。

子宮筋腫は、単一の結節（1つの成長）として成長することもあれば、集団で成長することもあります。子宮筋腫の集塊の大きさは、直径1ミリから20センチ以上、あるいはそれ以上のものまであります。比較のために、子宮筋腫は種子ほど小さいこともあれば、スイカほど大きいこともあります。子宮筋腫は、子宮壁内、子宮内腔内、子宮外面に発生することがあります。

治療オプションの進歩が子宮筋腫治療市場の成長を大きく後押ししています。

治療オプションの進歩は、子宮筋腫市場の成長の主要な促進要因の一つです。これらの技術革新は、従来の治療法よりも安全で、より効果的で、低侵襲な選択肢を提供し、回復時間の短縮、合併症発生率の低下、より良い治療成績など、患者に多くのメリットをもたらします。マイフェンブリーやイセルティのような新薬は、子宮筋腫の成長を助長するホルモンレベルを低下させることで子宮筋腫を治療することが承認されています。これらの内服薬は、手術に代わる非侵襲的な選択肢を提供します。

例えば、2022年8月、Myovant SciencesとPfizer Inc.は、閉経前女性における子宮内膜症に伴う中等度から重度の疼痛管理のための1日1回1錠の治療薬として、マイフェンブリー（relugolix 40mg、estradiol 1mg、norethindrone acetate 0.5mg）が米国食品医薬品局（FDA）により承認され、治療期間は最長24カ月であると発表しました。また、マイフェンブリーは、閉経前女性における子宮筋腫に伴う月経多量出血に対しても承認されています。

さらに、2022年6月、欧州委員会（EC）は、経口GnRH拮抗薬であるイセルティ（一般名：リンザゴリックス）について、生殖年齢にある成人女性（18歳以上）における中等度から重度の子宮筋腫（UF）症状の治療を適応症とする販売承認を付与しました。

認知度の低さと診断の遅れは、子宮筋腫治療市場の成長を妨げる重要な要因です。多くの女性が子宮筋腫の状態や症状、利用可能な治療法を知らないため、診断や治療が後手に回ることが多いです。これが市場成長の障壁となっています。

多くの女性は、月経多量出血、骨盤痛、頻尿などの子宮筋腫の症状を認識していません。この認識不足により診断が遅れ、子宮筋腫が大きくなったり治療が複雑になったりすることが多くなります。例えば、米国産科婦人科学会によると、子宮筋腫のある女性の60％までは、深刻な症状が出るまで子宮筋腫があることに気づいていないことが研究で示唆されています。

子宮筋腫と診断されるまでに、多くの女性が子宮摘出術など、より侵襲的で複雑な治療を必要とする可能性がありますが、早期の介入によって回避できた可能性があります。女性が適切な時期に医師の診断を受けない場合、子宮動脈塞栓術（UAE）や子宮筋腫核出術のような早期治療の機会を逃してしまいます。

当レポートでは、世界の子宮筋腫治療市場について調査し、市場の概要とともに、タイプ別、治療別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 経営者の洞察と重要なポイント

第3章 市場力学

• 影響要因
  • 促進要因
  • 抑制要因
  • 機会
  • 影響分析

第4章 戦略的洞察と業界展望

• 市場のリーダーとパイオニア
• 最新の開発とブレークスルー
• 規制と償還の情勢
• ポーターのファイブフォース分析
• サプライチェーン分析
• 特許分析
• SWOT分析
• アンメットニーズとギャップ
• 市場参入と拡大のための推奨戦略
• シナリオ分析ベストケース、ベースケース、ワーストケースの予測
• 価格分析と価格動向
• キーオピニオンリーダー

第5章 子宮筋腫治療市場（タイプ別）

• 筋層内筋腫
• 粘膜下筋腫
• 漿膜下筋腫
• 有茎性子宮筋腫

第6章 子宮筋腫治療市場（治療別）

• ホルモン療法
• ゴナドトロピン放出ホルモン（GnRH）拮抗薬
• GnRHアゴニスト
• プロゲスチン
• 選択的プロゲステロン受容体モジュレーター（SPRM）
• 外科的治療

第7章 子宮筋腫治療市場、地域別市場分析と成長機会

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他
• 南米
  • ブラジル
  • アルゼンチン
  • その他
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他
• 中東・アフリカ

第8章 競合情勢と市場ポジショニング

• 競合状況の概要と主要市場参入企業
• 市場シェア分析とポジショニングマトリックス
• 戦略的パートナーシップ、合併・買収
• 製品ポートフォリオとイノベーションにおける主な発展
• 企業ベンチマーク

第9章 企業プロファイル

• AbbVie Inc.
• 会社概要
• 製品ポートフォリオ
• 財務概要
• 主な発展
• SWOT分析
• Pfizer Inc.
• AstraZeneca
• Kissei Pharmaceutical Co., Ltd.
• Theramex

第10章 仮定と調査手法

第11章 付録

The global uterine fibroids treatment market size reached US$ 1.58 billion in 2024 and is expected to reach US$ 3.57 billion by 2033, growing at a CAGR of 9.5% during the forecast period 2025-2033.

Uterine fibroids (also called leiomyomas) are growths made of muscle and tissue that form in or on the wall of the uterus. These growths are usually benign and are the most common noncancerous tumors in females. Uterine fibroids can cause a variety of symptoms like pain and heavy, irregular vaginal bleeding. Sometimes, a person has no symptoms and is unaware they have fibroids. Treatment for fibroids typically depends on the severity of the symptoms.

Fibroids can grow as a single nodule (one growth) or in a cluster. Clusters of fibroids can range in size from 1 millimeter to more than 20 centimeters (8 inches) in diameter or even larger. For comparison, fibroids can be as small as a seed or as large as a watermelon. These growths can develop within the wall of the uterus, inside the main cavity of the uterus, or on the outer surface of the uterus.

Market Dynamics: Drivers & Restraints

Rising advancements in treatment options are significantly driving the uterine fibroids treatment market growth.

Advancements in treatment options are one of the key drivers of growth in the uterine fibroids market. These innovations offer safer, more effective, and minimally invasive alternatives to traditional treatments, providing numerous benefits for patients, including reduced recovery time, lower complication rates, and better outcomes. New drugs like Myfembree and Yselty have been approved to treat fibroids by reducing the hormone levels that contribute to fibroid growth. These oral medications provide a non-invasive alternative to surgery.

For instance, in August 2022, Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a one-pill, once-a-day therapy for the management of moderate to severe pain associated with endometriosis in pre-menopausal women, with a treatment duration of up to 24 months. MYFEMBREE is also approved for heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.

Additionally, in June 2022, the European Commission (EC) granted Marketing Authorization for Yselty (linzagolix), an oral GnRH antagonist, indicated for the treatment of moderate to severe symptoms of Uterine Fibroids (UF) in adult women (over 18 years of age) of reproductive age.

Limited awareness and delayed diagnosis hamper the market growth

Limited awareness and delayed diagnosis are significant factors that hamper the growth of the uterine fibroids treatment market. Many women are unaware of the condition, its symptoms, and available treatments, which often leads to late-stage diagnosis and treatment. This creates barriers to market growth.

Many women do not recognize the symptoms of uterine fibroids, such as heavy menstrual bleeding, pelvic pain, and frequent urination. This lack of awareness results in late diagnosis, often when the fibroids have grown larger or become more complicated to treat. For instance, according to the American College of Obstetricians and Gynecologists, studies suggest that up to 60% of women with uterine fibroids are unaware that they have them until they experience severe symptoms.

By the time fibroids are diagnosed, many women may require more invasive or complex treatments, such as a hysterectomy, which could have been avoided with earlier intervention. When women do not seek medical advice on time, they miss the opportunity for early-stage treatments like uterine artery embolization (UAE) or myomectomy, which could be less invasive and more effective in preserving fertility and overall health.

Segment Analysis

The global uterine fibroids treatment market is segmented based on type, treatment, and region.

Treatment:

The surgical treatment segment is expected to dominate the uterine fibroids treatment market with the highest market share.

Surgical treatment remains an effective treatment for uterine fibroids, primarily due to its high efficacy in completely removing fibroids, providing long-term relief from symptoms, and widespread availability. The best treatment for uterine fibroids depends on individual factors, but options range from medication to surgery, with myomectomy (surgical removal of fibroids) being a common choice for those wanting to preserve their uterus, and hysterectomy (removal of the uterus) for those who don't want to get pregnant in the future.

The only permanent solution for uterine fibroids, that it eliminates the possibility of fibroid recurrence. Recommended for women experiencing severe symptoms (e.g., heavy menstrual bleeding, chronic pelvic pain) who do not plan to conceive. For instance, the National Uterine Fibroids Foundation states that a hysterectomy is performed in 30-40% of fibroid cases due to its definitive nature. Over 200,000 hysterectomies are performed annually in the U.S. due to fibroids, making it one of the most common surgical procedures among women.

Geographical Analysis

North America is expected to hold a significant position in the global uterine fibroids treatment market with the highest market share

Uterine fibroids affect 60-80% of women of reproductive age, and the condition is particularly prevalent among African American women, with studies showing that African American women are 2-3 times more likely to develop fibroids compared to Caucasian women. For instance, according to the Centers for Disease Control and Prevention (CDC), uterine fibroids are one of the most common reasons for hysterectomies in the United States, with about 200,000 surgeries performed annually for fibroids. In the United States, nearly 1 in 5 women are affected by uterine fibroids during their lifetime, driving high demand for treatment options.

North America benefits from some of the best healthcare facilities in the world, including specialized centers for gynecology and women's health, which are equipped with state-of-the-art medical technologies for diagnosing and treating uterine fibroids. For instance, the Cleveland Clinic, Johns Hopkins Medicine, and other prominent hospitals offer minimally invasive surgeries like robotic-assisted myomectomy and MRI-guided Focused Ultrasound (MRgFUSl), positioning the region at the forefront of fibroid treatment innovation.

There has been a growing focus on women's reproductive health in North America, resulting in increased awareness about uterine fibroids and their associated symptoms, including heavy bleeding, pelvic pain, and infertility. This has led to more women seeking medical care and treatment options. For instance, in 2021, the Fibroid Foundation in the U.S. conducted awareness campaigns that helped highlight the impacts of uterine fibroids, raising awareness among women and encouraging early diagnosis and treatment.

Competitive Landscape

Top companies in the uterine fibroids treatment market include AbbVie Inc., Pfizer Inc., AstraZeneca, Kissei Pharmaceutical Co., Ltd., and Theramex, among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global uterine fibroids treatment market report delivers a detailed analysis with 39 key tables, more than 41 visually impactful figures, and 198 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Type
• 2.4. Snippet by Treatment
• 2.5. Snippet by Region

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Rising Advancements in Treatment Options
    • 3.1.1.2. Development of Hormonal Therapies
  • 3.1.2. Restraints
    • 3.1.2.1. Limited Awareness and Delayed Diagnosis
    • 3.1.2.2. Side Effects Associated with the Treatments
  • 3.1.3. Opportunity
    • 3.1.3.1. Focus on Fertility-Preserving Treatments
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established Leaders with Largest Marketing Brand
  • 4.1.3. Market Leaders with Established Products
• 4.2. Latest Developments and Breakthroughs
• 4.3. Regulatory and Reimbursement Landscape
  • 4.3.1. North America
  • 4.3.2. Europe
  • 4.3.3. Asia Pacific
  • 4.3.4. South America
  • 4.3.5. Middle East & Africa
• 4.4. Porter's Five Forces Analysis
• 4.5. Supply Chain Analysis
• 4.6. Patent Analysis
• 4.7. SWOT Analysis
• 4.8. Unmet Needs and Gaps
• 4.9. Recommended Strategies for Market Entry and Expansion
• 4.10. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.11. Pricing Analysis and Price Dynamics
• 4.12. Key Opinion Leaders

5. Uterine Fibroids Treatment Market, By Type

• 5.1. Introduction
  • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 5.1.2. Market Attractiveness Index, By Type
• 5.2. Intramural Fibroids*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 5.3. Submucosal Fibroids
• 5.4. Subserosal Fibroids
• 5.5. Pedunculated Fibroids

6. Uterine Fibroids Treatment Market, By Treatment

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 6.1.2. Market Attractiveness Index, By Treatment
• 6.2. Hormone Therapy*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Leuprolide Acetate
  • 6.2.4. Estradiol
  • 6.2.5. Norethindrone Acetate
  • 6.2.6. Others
• 6.3. Gonadotropin-Releasing Hormone (GnRH) Antagonists
  • 6.3.1. Elagolix
  • 6.3.2. Relugolix
  • 6.3.3. Linzagolix
• 6.4. GnRH Agonists
  • 6.4.1. Nafarelin
  • 6.4.2. Buserelin
  • 6.4.3. Triptorelin
  • 6.4.4. Others
• 6.5. Progestins
  • 6.5.1. Medroxyprogesterone Acetate
  • 6.5.2. Megestrol Acetate
• 6.6. Selective Progesterone Receptor Modulators (SPRMs)
  • 6.6.1. Mifepristone
  • 6.6.2. Ulipristal
  • 6.6.3. Telapristone
  • 6.6.4. Onapristone
  • 6.6.5. Others
• 6.7. Surgical Treatment
  • 6.7.1. Myomectomy
  • 6.7.2. Hysterectomy
  • 6.7.3. Uterine Fibroid Embolization
  • 6.7.4. Radiofrequency Ablation
  • 6.7.5. Endometrial Ablation

7. Uterine Fibroids Treatment Market, By Regional Market Analysis and Growth Opportunities

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 7.1.2. Market Attractiveness Index, By Region
• 7.2. North America
  • 7.2.1. Introduction
  • 7.2.2. Key Region-Specific Dynamics
  • 7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.2.5.1. U.S.
    • 7.2.5.2. Canada
    • 7.2.5.3. Mexico
• 7.3. Europe
  • 7.3.1. Introduction
  • 7.3.2. Key Region-Specific Dynamics
  • 7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.3.5.1. Germany
    • 7.3.5.2. UK
    • 7.3.5.3. France
    • 7.3.5.4. Spain
    • 7.3.5.5. Italy
    • 7.3.5.6. Rest of Europe
• 7.4. South America
  • 7.4.1. Introduction
  • 7.4.2. Key Region-Specific Dynamics
  • 7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.4.5.1. Brazil
    • 7.4.5.2. Argentina
    • 7.4.5.3. Rest of South America
• 7.5. Asia-Pacific
  • 7.5.1. Introduction
  • 7.5.2. Key Region-Specific Dynamics
  • 7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.5.5.1. China
    • 7.5.5.2. India
    • 7.5.5.3. Japan
    • 7.5.5.4. South Korea
    • 7.5.5.5. Rest of Asia-Pacific
• 7.6. Middle East and Africa
  • 7.6.1. Introduction
  • 7.6.2. Key Region-Specific Dynamics
  • 7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

8. Competitive Landscape and Market Positioning

• 8.1. Competitive Overview and Key Market Players
• 8.2. Market Share Analysis and Positioning Matrix
• 8.3. Strategic Partnerships, Mergers & Acquisitions
• 8.4. Key Developments in Product Portfolios and Innovations
• 8.5. Company Benchmarking

9. Company Profiles

• 9.1. AbbVie Inc.*
  • 9.1.1. Company Overview
  • 9.1.2. Product Portfolio
    • 9.1.2.1. Product Description
    • 9.1.2.2. Product Key Performance Indicators (KPIs)
    • 9.1.2.3. Historic and Forecasted Product Sales
    • 9.1.2.4. Product Sales Volume
  • 9.1.3. Financial Overview
    • 9.1.3.1. Company Revenue
    • 9.1.3.2. Geographical Revenue Shares
    • 9.1.3.3. Revenue Forecasts
  • 9.1.4. Key Developments
    • 9.1.4.1. Mergers & Acquisitions
    • 9.1.4.2. Key Product Development Activities
    • 9.1.4.3. Regulatory Approvals, etc.
  • 9.1.5. SWOT Analysis
• 9.2. Pfizer Inc.
• 9.3. AstraZeneca
• 9.4. Kissei Pharmaceutical Co., Ltd.
• 9.5. Theramex

LIST NOT EXHAUSTIVE

10. Assumption and Research Methodology

• 10.1. Data Collection Methods
• 10.2. Data Triangulation
• 10.3. Forecasting Techniques
• 10.4. Data Verification and Validation

11. Appendix

• 11.1. About Us and Services
• 11.2. Contact Us